Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Seynaeve

Showing results (61-70 of 175) with videos related to

Pageof 18
Sort By:
Acta Oncologica (Stockholm, Sweden)|November 11, 2014
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysisJohanna G H van Nes, Louk V A M Beex, Caroline Seynaeve, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 19, 2013
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trialMarjan van Hezewijk, Esther Bastiaannet, Hein Putter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up studyIris van Oostrom, Hanne Meijers-Heijboer, Litanja N Lodder, et al.
Breast Cancer Research and Treatment|October 24, 2007
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patientsMieke Kriege, Caroline Seynaeve, Hanne Meijers-Heijboer, et al.
Breast Cancer Research and Treatment|August 3, 2010
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer familiesAntoinette Hollestelle, Cory Pelletier, Maartje Hooning, et al.
Psycho-Oncology|August 16, 2006
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationshipsIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Annals of Surgical Oncology|June 2, 2007
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer ClinicBernadette A M Heemskerk-Gerritsen, Cecile T M Brekelmans, Marian B E Menke-Pluymers, et al.
Journal of Cancer Research and Clinical Oncology|May 11, 2015
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriersMieke Kriege, Agnes Jager, Antoinette Hollestelle, et al.
Journal of Medical Genetics|June 13, 2019
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-<i>BRCA1/2</i> breast cancer familiesInge M M Lakeman, Florentine S Hilbers, Mar Rodríguez-Girondo, et al.
Breast Cancer Research and Treatment|March 5, 2014
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trialDuveken B Y Fontein, Daniel Houtsma, Johan W R Nortier, et al.
Pageof 18

Showing results (61-70 of 175) with videos related to

Sort By:
Pageof 18
Acta Oncologica (Stockholm, Sweden)|November 11, 2014
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysisJohanna G H van Nes, Louk V A M Beex, Caroline Seynaeve, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 19, 2013
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trialMarjan van Hezewijk, Esther Bastiaannet, Hein Putter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2003
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up studyIris van Oostrom, Hanne Meijers-Heijboer, Litanja N Lodder, et al.
Breast Cancer Research and Treatment|October 24, 2007
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patientsMieke Kriege, Caroline Seynaeve, Hanne Meijers-Heijboer, et al.
Breast Cancer Research and Treatment|August 3, 2010
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer familiesAntoinette Hollestelle, Cory Pelletier, Maartje Hooning, et al.
Psycho-Oncology|August 16, 2006
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationshipsIris van Oostrom, Hanne Meijers-Heijboer, Hugo J Duivenvoorden, et al.
Annals of Surgical Oncology|June 2, 2007
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer ClinicBernadette A M Heemskerk-Gerritsen, Cecile T M Brekelmans, Marian B E Menke-Pluymers, et al.
Journal of Cancer Research and Clinical Oncology|May 11, 2015
Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriersMieke Kriege, Agnes Jager, Antoinette Hollestelle, et al.
Journal of Medical Genetics|June 13, 2019
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-<i>BRCA1/2</i> breast cancer familiesInge M M Lakeman, Florentine S Hilbers, Mar Rodríguez-Girondo, et al.
Breast Cancer Research and Treatment|March 5, 2014
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trialDuveken B Y Fontein, Daniel Houtsma, Johan W R Nortier, et al.
Pageof 18